N
Nurix
Develops small molecule inhibitors for the treatment of proliferative and degenerative diseases
About Nurix
Nurix Therapeutics is a biotechnology company focused on discovering and developing drugs that harness the natural process of protein degradation to treat a wide range of diseases. The company's core technology revolves around controlling ubiquitin E3 ligases, which are key enzymes responsible for protein breakdown in human cells. By targeting these enzymes, Nurix aims to develop novel therapeutic agents, particularly in the field of oncology, including small molecule immuno-oncology agents.
Nurix operates in the biopharmaceutical market, primarily serving patients with cancer and other serious diseases. The company employs a business model that involves drug discovery and development, with revenue generated through partnerships, licensing agreements, and potential future sales of its proprietary drugs.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
Open roles
Nurix in the Brisbane ecosystem
The Nurix office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
The Column Group
Third Rock Ventures
Series B and later6 investors entered at this stage
Foresite Capital
Boxer Capital
Wellington Management
Redmile Group
EcoR1 Capital
Bain Capital Life Sciences
Source: Dealroom Talent Intelligence.
Patents
38 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Nurix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Sanofi discontinues Nurix's Phase 1 STAT6 degrader SAR448272
